LeMaitre Vascular Reports Strong Q1 Results and Raises Full-Year Guidance
LMAT sits 44% above its 52-week low of $78.01.
Summary
LeMaitre Vascular reported exceptionally strong Q1 2026 financial results, with sales up 11% and EPS up 42%, leading the company to raise its full-year guidance for both sales and adjusted EPS.
Key Events · Earnings and Guidance · LMAT
-
Strong Q1 2026 Financial Performance
LeMaitre Vascular reported Q1 2026 sales of $66.6 million, an 11% increase year-over-year, and diluted EPS of $0.68, a 42% increase, significantly exceeding prior year results due to higher ASPs, geographic expansion, and manufacturing efficiencies.
-
Raised Full-Year 2026 Guidance
The company increased its full-year 2026 guidance, projecting midpoint sales of $280 million (+12% organic) and adjusted EPS of $3.00 (+26% adjusted), signaling strong confidence in continued growth and operational leverage.
-
Quarterly Dividend Declared
The Board of Directors approved a quarterly dividend of $0.25 per share, consistent with the 25% increase announced earlier in the year, payable on June 4, 2026.
Analysis · LMAT · Industrial Applications And Services
LeMaitre Vascular's strong Q1 performance, marked by double-digit growth in sales and a significant 42% increase in EPS, demonstrates robust operational execution and market demand for its vascular devices. The decision to raise full-year guidance, particularly for sales and adjusted EPS, signals management's confidence in sustained momentum and operational leverage. This positive financial update, following a recent news report on the same day, reinforces a strong investment thesis and could lead to positive investor sentiment.
At the time of this filing, LMAT was trading at $112.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $78.01 to $118.01. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.